1.
Cancer Treat Rep
; 69(11): 1275-7, 1985 Nov.
Article
in English
| MEDLINE
| ID: mdl-3867402
ABSTRACT
Patients with advanced inoperable or recurrent adenocarcinoma of the stomach received an iv bolus of epirubicin (75 mg/m2) every 3 weeks. Partial responses were observed in four of 24 evaluable patients (17%). Treatment was generally well tolerated; a drop in left ventricular ejection fraction was observed in one patient who had received 450 mg/m2 of epirubicin.
Subject(s)
Doxorubicin/therapeutic use , Stomach Neoplasms/drug therapy , Adenocarcinoma/drug therapy , Adult , Aged , Anemia/chemically induced , Doxorubicin/adverse effects , Drug Evaluation , Epirubicin , Female , Humans , Male , Middle Aged , Stroke Volume/drug effects
2.
Cancer Treat Rep
; 69(7-8): 917-8, 1985.
Article
in English
| MEDLINE
| ID: mdl-4016799
3.
Cancer Treat Rep
; 67(1): 89-90, 1983 Jan.
Article
in English
| MEDLINE
| ID: mdl-6311414